Meta-analyses of randomised trials: when the whole is more than just the sum of the parts. by Parmar, M. K. et al.
British Journal of Cancer (1996) 74, 496-501
fft (C) 1996 Stockton Press All rights reserved 0007-0920/96 $12.00
GUEST EDITORIAL
Meta-analyses of randomised trials: when the whole is more than just the
sum of the parts
MKB Parmarl, LA Stewart' and DG Altman2
'MRC Cancer Trials Office, 5 Shaftesbury Road, Cambridge, CB2 2BW; 2ICRF Medical Statistics Group, Centrefor Statistics in
Medicine, Institute ofHealth Sciences, PO Box 777, Oxford OX3 7LF, UK.
Keywords: meta-analysis; randomised and systematic review
A meta-analysis can be defined as an exhaustive, objective,
quantitative, systematic review of the best available evidence
addressing a specific question. In practice, this means that
most meta-analyses in medical research involve the summary,
presentation and quantitative combination of the results of
all relevant randomised trials.
Meta-analyses have had an important impact on
oncological practice, for example in the adjuvant treatment
of women with early breast cancer (Early Breast Cancer
Trialists' Collaborative Group, 1992a, and b), and in
providing the basis for designing further trials, for example
in the treatment of women with locally advanced ovarian
cancer (Advanced Ovarian Cancer Trialists' Group, 1991).
Nevertheless, the use of meta-analyses is still the subject of
some controversy. Current issues include the following. Is a
meta-analysis a purely objective and mechanical exercise?
Should some allowance be made for the quality of each trial?
What is the definition of a good meta-analysis? What does
the overall result from a meta-analysis mean? Here we offer a
practical approach, giving the principal reasons for perform-
ing a meta-analysis, discussing tricky issues in the design,
conduct and analysis, and giving some advice on the
appropriate interpretation of the results of meta-analyses.
As illustration, we consider two published examples of
meta-analysis in oncology. These are both taken from
publications describing a number of meta-analyses which
address questions in the treatment of women with early
breast cancer (Early Breast Cancer Trialists' Group, 1992a, b)
and advanced ovarian cancer (Advanced Ovarian Cancer
Trialists' Group, 1991).
Example 1: Adjuvant chemotherapy in early breast cancer
The first randomised trial of surgery plus CMF chemother-
apy (cyclophosphamide, methotrexate and 5-fluorouracil) vs
surgery alone in women with early breast cancer was reported
in 1976 by Bonadonna and colleagues (Bonadonna et al.,
1976). Over the next 10 years numerous trials were
performed, all addressing this same question and, in 1988,
a meta-analysis of all randomised trials was published (Early
Breast Cancer Trialists' Collaborative Group, 1988). Updated
results of this meta-analysis were published in 1992 (Early
Breast Cancer Trialists' Collaborative Group, 1992b) and an
adapted version of these results is reproduced in Figure 1.
Using the most straightforward method of analysis (fixed
effect method -see analysis section) the combined pooled
hazard ratio (HR) across trials is shown by the diamond
underneath each set of trials. The centre of the diamond gives
the overall estimated effect combined across the set of trials
and the ends of the diamond give the 95% confidence interval
for this estimate. Notice that in this example there are three
such combined estimates, the first for trials using CMF, the
second for trials using CMF with extra drugs, the third for
both sets of trials. It can be seen that the overall pooled
hazard ratio is 0.82, which indicates an 18% reduction in
death rate associated with the use of CMF (95% confidence
interval: 11% to 25%). It should be noted that, in the
analyses presented in the paper, annual odds ratios were used
and reported. However, when the number of deaths in each
year is relatively small, the annual odds ratio is an estimate of
the hazard ratio.
Example 2: Carboplatin vs cisplatin in locally advanced
ovarian cancer
The first randomised trial comparing single-agent carboplatin
with single-agent cisplatin in women with locally advanced
ovarian cancer was started in 1981 (Wiltshaw et al., 1985).
Over the next 10 years a further ten trials were performed
comparing these same drugs as either single agents (two
further trials) or in combination with other drugs (eight
trials). In 1991 a meta-analysis of these 11 trials was
published (Advanced Ovarian Cancer Trialists, Group,
1991). The results of this meta-analysis are slightly adapted
and reproduced in Figure 2. The overall hazard ratio of 1.06
suggests an estimated 6% increase in the relative risk of death
with carboplatin. However, the confidence interval (95%
confidence interval - 6% to + 16%) and the P-value indicate
there is no good evidence that either cisplatin or carboplatin
is better.
Why do we need meta-analyses?
The main reason for performing meta-analyses is simple:
conclusions on the relative merits of different treatments
should be based on the evidence available from all relevant
randomised trials. Unfortunately, it is all too common for
individual 'well-publicised' trials, which have produced the
most striking results, to be emphasised. Thus, in the early
breast cancer example (Figure 1) it would be tempting, but
inappropriate, to emphasise trials 79E and 80F above all the
other trials of CMF just because they produced the most
positive and statistically significant results (Gotzsche, 1987).
Conversely, it would be equally inappropriate to emphasise
just those trials to the right of the solid line that suggested no
evidence of a benefit from chemotherapy.
Size of treatment effects
Most new treatments are likely to improve survival only by a
moderate amount. The two examples also show that, where
the treatment effect is small, individual trials are rarely large
enough to produce a clear result, which is the second big
advantage of meta-analyses-they include large numbers of
patients and reduce random error ('the play of chance'). In
the breast cancer example only two relatively small trials give
a 'significant result' at the P=0.01 level. Most of the trials
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No. events/ no. entered
Reference Chemotherapy Control 0- E Variance Estimated hazard ratio
CMF
73B
75E
76C
76E
77B
78E
78K
79E
80F
80J
82C
118/ 210
29 / 55
62 / 112
77 / 229
82/201
69/247
75/ 171
64/ 185
6 / 49
12/30
144/609
Subtotal 738/2096
CMF with extra drugs
76H 181/294
77G 34/81
78V 50/87
79B 84/325
79C 21/64
81H 30/276
83B 20/171
Subtotal 420 / 1298
Total 1578/3396
120/ 181
26/54
67/103
92 / 223
104/196
63/241
91 / 164
107/206
19 / 47
10 / 29
160 / 634
-13.4
1.20
-7.50
-11.6
-15.6
1.90
-10.3
-23.5
-7.60
1.40
-6.90
859/2078 -91.8
193/275
35 / 82
48/95
72/316
26/73
42 / 265
21 / 171
-18.8
-1.90
3.00
7.50
-2.90
-7.00
-1.10
437/1277 -21.2
1296/3355 -113
54.50
12.80
28.00
39.40
43.00
29.10
37.30
38.50
5.70
5.00
69.40
362.6
81.70
16.00
21.90
36.50
10.60
17.40
9.90
193.9
556.5
I. 0
4
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-tzM?2
4111b.. ......I.
0.78(0.54-1.10)
1.10(0.53-2.26)
0.76 (0.47 - 1.24)
-~~~~~~~ ~~0.74(0.49-1.12)
0.70 (0.47 - 1.04)
0 ~~~~~~~1.07 (0.66-1.73)
.1-I ~~~~~~~0.76 (0.50-1.16)
0.54 (0.36 - 0.82)
0.26 (0.09 - 0.77)
1.32 (0.42-4.18)
0.91 (0.67 - 1.24)
0.78 (0.70 - 0.86)
0.79 (0.59 - 1.05)
I 0.89(0.47-1.70)
p t~~~~~~~1.15 (0.66-2.00)
0 I ~~~~~~1.23 (0.81-1.89)
I 0.76 (0.34 - 1.68)
-'----A ~~~~~~1.67 (0.36-1.24)
0.89 (0.39 - 2.02)
0.90 (0.78 - 1.04)
0.82 (0.75 - 0.89)
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Figure 1 Meta-analysis and estimated hazard ratios for the end point of death from randomised trials of adjuvant CMF-based
chemotherapy in women with early breast cancer. This figure is adapted from Figure 13M in the reference: Early Breast Cancer
Trialists' Collaborative Group, 1992b. For each trial the number of deaths (events) and the number of patients randomised are
given. The statistic 0-E is the difference between the observed (0) and expected (E) deaths for the new treatment. The expected
deaths are calculated using a log-rank type analysis for survival type data. The statistic V, the Mantel Haenszel variance, is a
measure of the information contained in the trial. (Parmar and Machin, 1995). Under the assumption that there is no difference
between the two arms, 0-E should differ only randomly from zero. [Similarly the total (0-E)) should also differ only randomly
from zero.] The statistic V, the variance, is a measure of the information contained in the trial. So, the trial labelled 73B, with
V =54.5, has almost 11I times more information than the trial labelled 80J with V = 5. Figure 1 shows the hazard ratio (HR) for each
trial, calculated using the expression exp [(0-E)/V], and represented by the centre of the open square. The area of the square is
proportional to V, the amount of information. The hazard ratio given at the end of each line is a measure of the relative death rates
in the two arms of the trial: a value of 1 represents no difference in death rates. The value of 0.78 for trial 73B represents a
reduction in the death rate of 22% [(1 -0.78) x 100%] as a result of the adjuvant use of CMF. A value larger than 1 represents an
increase in death rate associated with the use of CMF. Confidence intervals for the hazard ratio estimate for each trial are given by
the lines either side of the square. The inner ticks represent the 95% interval, while the outer ticks represent the 99% interval. The
99% interval is also given numerically in brackets at the end of the line. If the line between the inner ticks does not cross the
equivalence line 1, then the trial has produced a result significant at the 5% level (that is P<0.05). Similarly, if the line enclosed in
the outer ticks does not cross the equivalence line the trial has produced a result significant at the 1% level (that is P<0.01).
Although not all reports of a meta-analysis give both intervals for each trial, it is recommended that they do so.
No. events/ no. entered
Reference Carboplatin Cisplatin 0- E Variance Estimated hazard ratio
Single agent
Adams
Mangioni
Wiltshaw
37 / 45
54 / 88
57 / 67
Subtotal 148 / 200
Combination
Alberts 105/168
Anderson 14/27
Conte 55 / 83
Edmonson 37 /50
Kato 4/28
Meerphol 31 /91
Pater 123 /224
ten Bokkel 106 /167
Huinink
Subtotal 475 / 838
Total 623 /1038
32 / 43
47 / 85
54 / 64
133 /192 7.10
102 /170
22 /29
49 / 82
33/54
/ 23
21 /82
126 /223
97 / 168
1.00
4.30
1.60
6.00
-1.50
3.90
-1.00
5.30
455 /831 9.00
588 /1023 16.10
2.10 17.21
4.00 25.21
1.00 27.74
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Figure 2 Meta-analysis and estimated hazard ratios for the end point of death from randomised trials replacing cisplatin with
carboplatin in women with advanced ovarian cancer. This figure is adapted from Figure 10 in the reference: Advanced Ovarian
Cancer Trialists' Group, 1991.
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are inconclusive -the confidence intervals straddle unity.
However, the result combined across all trials is much more
reliable with narrow confidence limits and a P-value of less
than 0.00001. Similarly, for ovarian cancer example, the
confidence intervals for each of the individual trials are so
wide that within each trial even relatively large differences
between the effect of carboplatin and cisplatin cannot be
excluded.
These examples also show that to distinguish reliably
between a moderate effect and no effect is difficult, often
requiring the observation of at least 500 events in a two arm
trial. This in turn will usually require many thousands of
patients to be randomised. While we can hope that some such
trials are performed, in many circumstances such numbers of
patients can be achieved only through a meta-analysis.
Subgroup analysis
When assessing the role of any new treatment an important
additional question is whether the treatment is equally
effective in well-defined subgroups of patients. For example,
is the treatment more or less effective in males or females, or
in old or young patients? In statistical terms, a lack of
consistency of effect across subgroups is termed an
interaction. Statistical tests for interaction are not very
powerful and any individual trial, unless it is very large,
has little chance (low power) of picking up such interactions
should they exist. It is more likely that an analysis for
interaction in an individual trial will, by chance, throw up
spurious interactions (Simon and Altman, 1994). The
increased numbers of events in a meta-analysis offers the
best, and probably only, opportunity to assess whether any
treatment effect is consistent across well-defined subgroups of
patients. But even in a meta-analysis with 500 events, a test
for interaction can be misleading.
Designing new trials
A meta-analysis of all previous randomised trials should be
considered a 'must' before initiating further randomised
trials. Meta-analyses have provided the basis and impetus
for conducting large national and international trials. For
example, a meta-analysis of randomised trials of chemother-
apy for women with locally advanced ovarian cancer
(Advanced Ovarian Cancer Trialists' Group, 1991) led to
two international trials in early and advanced disease -
ICON 1 and ICON 2 (International Collaborative Ovarian
Neoplasm studies 1 and 2) - both aiming to recruit a
maximum of 2000 patients. By contrast the median size of
trials included in the meta-analysis was close to 150.
Similarly, the meta-analysis of trials of 5-fluorouracil portal
vein infusion in the adjuvant treatment of colorectal cancer
(Gray et al., 1991) led to a subsequent national trial (AXIS;
adjuvant X-ray and 5-FU infusion study) which is aiming for
a maximum of 4000 patients - the median size of previous
trials was 219.
No. events/no. entered
Trial Control New 0 - E Variance
A 67 / 100 33 / 100 -17.00 25.00
B 215/500 185/500 -15.00 100.00
Total 282 / 600 218 / 600 -32.00 125.00
-5.60 14.50
Design
Most meta-analyses combine the results from trials which are
somewhat different; for example, they may have different
protocols, different patient populations, different entry criteria
and may use slightly different treatments. It is therefore
inevitable that there will be clinical heterogeneity across trials
and sometimes the heterogeneity will be considerably. Some
argue that such heterogeneity can make the results of a meta-
analysis meaningless and that the emphasis should therefore
be placed on the results of individual trials. However, rather
than being a hazard, in many circumstances, clinical
heterogeneity can mean that the result of a meta-analysis
will have more practical relevance than the result of any
individual specific trial. In particular, if we can show that a
broad class of treatments is (or is not) effective for a broad
class of patients, the results can more reliably be extrapolated
to the general population, than if a specific treatment given a
particular way, to a tightly defined group of patients, in one
circumstance is (or is not) shown to be effective.
The issue of which trials are sufficiently similar that they
can be 'combined' in a meta-analysis is inevitably a subjective
decision based on the clinical and biological information
available on each treatment regimen. A useful approach is to
ask whether there is any good evidence to expect a different
direction of effect or markedly different size of effect with the
different regimes in the various trials. Without such evidence
it is usually best to include these trials in the meta-analysis
Just as for a clinical trial it is important to have a protocol
for a meta-analysis (Stewart and Clarke, 1995). This would
include eligibility criteria for trials, the need for each trial to
be properly randomised, a statement of which trials will be
considered together in the analysis and which subgroups will
be investigated to test for treatment interactions.
Conduct
A meta-analysis is usually initiated by performing a computer-
based literature search (Dickersin et al., 1994), which may or
may not be supplemented by other methods of searching for
trials. The results of each published randomised trial are then
summarised and combined. Many researchers only use
summaries ofdata extracted from easily identifiable published
reports as the basis for their conclusions (Gregory et al., 1992;
Himmel et al., 1986). However, recent evidence suggests that
sometimes this 'quick and dirty' approach can give misleading
results. Biases can arise from a number of different sources in
such literature-based meta-analyses. Forexample, the inclusion
oftrials which purport to be properly randomised but which in
fact are not; the exclusion of trials which remain unpublished
(publication bias), and the unavailable data from published
analyses which inappropriately excluded some patients. A
particular problem in oncology is that trials often report early
data with relatively little follow-up, making long-term results
unreliable. In a literature-based meta-analysis it is usually
Hazard ratio
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Figure 3 Meta-analysis and estimated hazard ratios for two (hypothetical) trials A and B. Results of the meta-analysis using both
the fixed and random effects methods are presented.difficult, if not impossible, to perform a reliable time-to-event
analysis. It is especially difficult when the end point is survival
time, as is usual in cancer trials. Also, retrieving the necessary
data from publications for any analysis can be difficult and
prone to considerable error.
At the other extreme, all individual patient data from all
randomised trials can be collected, checked and reanalysed-
an individual patient-based meta-analysis. In this approach, a
hugh effort is necessary to identify and obtain data from all
trials, both published and unpublished, and to obtain the
data (Stewart and Clarke, 1995). The randomisation for each
individual trial is checked, excluded patients are retrieved,
and detailed time-to-event analyses can be performed
(Advanced Ovarian Cancer Trialists' Group, 1991; Early
Breast Cancer Trialists' Group, 1992 a, b). Other important
advantages are that up-to-date data can be obtained, giving
more mature follow-up and hence a more sensitive and
reliable analysis, especially of long-term survival.
These two extremes of approach have been compared by
considering trials of combination platinum-based therapy vs
single-agent chemotherapy for women with locally advanced
ovarian cancer (Stewart and Parmar, 1992). A literature-
based meta-analysis included 739 patients from eight
published trials with a median follow-up of 3.5 years, while
the patient-based meta-analysis included 1339 patients from
11 trials with a median follow-up of 6.5 years. The literature-
based meta-analysis gave an estimated absolute improvement
in 30 month survival of 7.5% (from 25% to 32.5%) with a P-
value of 0.03; while the patient-based meta-analysis gave an
estimated improvement of 2.5% (from 25% to 27.5%) with a
P-value of 0.30. Thus the literature-based meta-analysis not
only provided a 'statistically significant' result but also gave
an estimated treatment effect which was three times that
obtained for the patient-based analysis. When balanced
against other factors such as toxicity, quality of life and
cost, the clinical interpretation of these two meta-analyses
could be quite different.
This is only one example, but it shows that in certain
circumstances the conclusions from the two extremes of meta-
analysis can differ considerably, although perhaps not always
in the direction seen in this example. These possible differences
become increasingly important when practical issues are
considered. A literature-based meta-analysis will typically
take no more than a few months to perform, while a
patient-based analysis will often take over 2 years to complete
(Stewart and Clarke, 1995). The patient-based meta-analysis is
therefore considerably more expensive than a literature-based
one, requiring considerable resources at all stages.
Although a useful first step, a literature-based meta-
analysis is likely to give an incomplete picture. It is usually
impossible to assess whether any treatment effect is similar in
well-defined subgroups of patients. The only way to do this
reliably is by collecting and analysing individual patient data
and information on prognostic factors. For example, until the
patient-based meta-analysis of adjuvant therapy for breast
cancer, there was a strong body of opinion that only
oestrogen receptor-positive patients would benefit from
adjuvant hormone therapy. The patient-based meta-analysis
showed that there was no good evidence to support this
assertion (Early Breast Cancer Trialists' Collaborative
Group, 1992a). A patient-based meta-analysis of adjuvant
radiotherapy for small-cell lung cancer showed that those
under the age of 55 showed the largest benefit while those
above the age of 70 probably achieved little or no benefit
(Pignon et al., 1992). Some argue (Simon, 1987) that the
ability to make such statements on effects in different
subgroups is reason enough to go to the effort of collecting
and analysing individual patient data.
There are some meta-analyses which lie between the two
extremes just described. For example, published data can be
supplemented with further summary data from trial
investigators (King et al., 1988); or summary statistics from
unpublished as well as published trials can be analysed (Gray
et al., 1991). These approaches may be adequate in certain
Meta-analysis of randomised trials
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circumstances, for example when the main end point is not
time to an event. In oncology, however, where the main end
point is usually time to an event, such as death, it is doubtful
whether such an approach will be satisfactory; a patient-
based meta-analysis is therefore preferable.
Analysis
Both examples discussed earlier use the fixed effect model,
which is the most straightforward and easiest to understand
method of analysis. However, the appropriate method of
analysis is far from agreed, and some argue that a random
effects model is a more appropriate way to analyse the data. To
illustrate the difference between the methods consider the
hypothetical example in Figure 3. This shows two trials
comparing a new treatment with a control with totals of 100
and 400 deaths in them. As for the data in the breast and
ovarian cancer examples, survival-type analysis was used to
analyse these data. However, to aid understanding, under some
simple assumptions (proportional hazards) the hazard ratios
correspond to an estimated absolute improvement in survival
of 20% (from 50% to 70%) in trial A and 5% (from 50% to
55%) in trial B when the control group survival is 50%.
As before the results of these two trials combined are
represented by the diamonds at the bottom ofthe plot. The two
diamonds represent the results forthe two principal methods of
analysis-the fixed effect model (Peto, 1987), and random
effects model (Dersimonian and Laird, 1986). In the simplest
fixed effect model the (O- E)s and Vs for the trials are summed
to obtain the combined 0-E and V respectively. In this
approach the contribution of each trial to the combined
estimate is proportional to the amount of information in it.
Thus, for example, Trial B contributes 80% (100/125) of the
information (remember that V provides an estimate of the
amount of information). This is an intuitively appealing
weighting scheme. With this model, however, no allowance is
made for any between-trial variability, only within-trial
variability is considered. In particular, in the example no
allowance is made for the fact thatestimated survival difference
in trial A is 20%, whereas in trial B it is only 5%. A test for
statistical heterogeneity between these two results gives a P-
value of 0.02 (x21 = 5.24), suggesting more than chance
variation between the results. The random effects model
explicitly allows for this variability by considering these two
trials to be a random sample from all possible trials. In
consequence, in the example the confidence interval for this
combined estimate is much wider than, in fact, the confidence
intervals for either trial. This difference is reflected in the fact
that the amount ofinformation for the combined result is only
14.5 (compared with 25 and 100 for the individual trials).
However, the estimate for the combined effect of0.69 is similar
to that from the fixed effect model of0.77. It is common to find
that the estimates from the two approaches are similar, but in
the presence ofstatistical heterogeneity the confidence interval
for the random effects estimate will be much wider than the
confidence interval for the fixed effect estimate. Ifthere is little
or no statistical heterogeneity between trials then both models
will produce similar results.
There are strong proponents of both approaches. Those in
favour of the random effects model argue that it formally
allows for between-trial variability, that the fixed effects
approach unrealistically assumes a single effect across all
trials and that the fixed effect model can overemphasise the
result because it does not allow for between-trial variability.
Those in favour of the fixed effect approach argue that the
random effects model is using a statistical model to address a
clinical problem. In particular, that it gives no insight into the
source of between trial variability. Further, the trials are not
a random sample-they are in fact all the trials that have
been performed.
The chi-square test for statistical heterogeneity is not very
powerful and will generally produce 'significant' results only
when there is gross heterogeneity between the results ofMeta-analysis of randomised trials
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individual trials. As we have said, we expect clinical
heterogeneity between trials, because of differing protocols,
treatments, patients etc., and this will be true irrespective of
whether the statistical test for heterogeneity is significant. If
statistical heterogeneity is observed, then this should be the
basis for investigating the possible explanations (Thompson,
1994). For example, perhaps the treatments are sufficiently
different and can be split into less heterogeneous groups;
perhaps dose or duration of treatment is the source of the
heterogeneity; or perhaps it has something to do with the
characteristics of the patients in the different trials. If a
source of heterogeneity is found, the trials can be subdivided
according to the appropriate characteristic and separate
analyses can be made. In particular, if there is such
heterogeneity, we may be able to approach answering
questions such as which treatments perform best or which
type of patients will benefit most from a particular treatment.
Modelling such heterogeneity using the random effects
approach is effectively throwing away valuable information.
In the search for the clinical source of statistical
heterogeneity, there is likely to be some post hoc reasoning
in the explanation, so that only cautious conclusions should
be drawn after such data-delving. Nevertheless, the aim
should be to minimise statistical heterogeneity within a
comparison, so that it becomes almost irrelevant which
model is used. Heterogeneity can be investigated fully only
when data on individual patients are available, particularly
when the end point is the time to an event. It is unlikely that
in a literature-based meta-analysis all reasonable possible
sources of heterogeneity can be investigated.
Interpretation
The patients included in randomised clinical trials are
inevitably a selected subpopulation (Begg and Engstrom,
1987) of those patients with the disease and the true
treatment effect is likely to vary in different situations, for
example, with different types of patients. Thus, when
extrapolating the results of a meta-analysis to different types
of patients, biological reasons for possible differences both in
size and direction of effect need to be considered. However,
unless there is good evidence for differences of effect in
different subgroups within the meta-analysis, the overall
average estimate available is the best summary of the results
of these trials, and because of the clinical heterogeneity of the
trials, it is also perhaps the best estimate of the effect in the
general population. The overall results of a meta-analysis
therefore provide the best summary on the main end points
from which each clinician, together with the patient, can
assess the relative merits of different treatments.
The issue ofwhat benefit is clinically worthwhile is clearly a
subjective decision, likely to be influenced by factors such as the
country, speciality ofthe clinician, patient-specific factors such
as age and stage of disease, quality of life considerations and
cost ofthe new treatment. For example, it is quite likely because
ofcultural differences that clinicians in the USA would accept a
much smaller benefit to use toxic chemotherapy than clinicians
in the UK (Parmar et al., 1996). It is also likely that oncologist
may accept smaller benefits as an indication to offer
chemotherapy than, for example, their surgical colleagues. In
some countries the cost of some new therapies may be so
prohibitive that it is impossible to give a new treatment unless
the observed effect is enormous, which is very unlikely.
An important consideration must also be the appropriate
interpretation of any survival benefit. For a number of good
reasons survival differences between treatments are measured
on a relative (the hazard ratio) scale. However, to aid
interpretation they should also be presented on the absolute
scale (Bobbio et al., 1994). For example, considering the
complete results of the adjuvant use of CMF (Early Breast
Cancer Trialists' Collaborative Group, 1992a,b), the esti-
mated improvement with polychemotherapy in women below
the age of 50 was a reduction in the relative risk of death by
25% (hazard ratio =0.75). Table I relates this relative
reduction in risk to an absolute improvement in survival
given different underlying prognoses. One interpretation of
this table could be that chemotherapy may be worthwhile for
women with a poor or medium underlying risk of death, but
that it may not be considered worthwhile for those with a
very good prognosis.
The positive result of adjuvant CMF chemotherapy in
women with early breast cancer highlights some of the
differences in interpretation. When the results were first made
available in the mid 1980s (Early Breast Cancer Trialists'
Collaborative Group, 1988) there were a number of opinions
of its interpretations and relevance around the world. For
many clinicians in the US the results served to confirm their
current treatment policy of routinely offering CMF
chemotherapy to many of their patients. In Italy, where the
CMF regimen was piloted, the results came as no great
surprise, again confirming the policy of routinely offering
CMF chemotherapy. In the UK, however, many clinicians
were still sceptical about the benefit. The overall relative
effect of CMF translated into an absolute survival benefit at 5
years across all stages of disease of 3.5% for all ages and 7%
for premenopausal women. These modest benefits had to be
balanced against the fact that CMF is a regimen that is
relatively toxic for up to a year. After the updated results
published in 1992 (adapted and presented in Figure 1),
however, there appeared to be a greater acceptance of the
role of CMF. This may be owing to a number of factors,
perhaps including 10 year survival advantages and more
conclusive results. The introduction of new and more effective
anti-emetic regimens over this period may also have helped.
Finally, the perception of a worthwhile effect may have
changed, with findings emerging that patients were willing to
accept fairly toxic regimens for relatively modest survival
benefits (Slevin et al., 1990).
In contrast to the above positive results for CMF in early
breast cancer, the example of cisplatin vs carboplatin in
advanced ovarian cancer shows no evidence of difference
between these two regimens. The estimated overall hazard
ratio was 1.06, slightly in favour of cisplatin, with a 95%
confidence interval of 0.94 to 1.18. The results translate into
an absolute difference in 2 year survival of 2% in favour of
cisplatin, with a 95% confidence interval of -3% to 6%.
These results offer no good evidence that cisplatin is either
superior or inferior to carboplatin and imply that if there is a
difference between them it is very small. Comparing the two
subtotals in Figure 2 also shows that there is no evidence of
difference when cisplatin is replaced by carboplatin in
combination regimens or as a single agent. Finally, it should
be noted that no individual study stood out as indicating a
significant benefit for either treatment.
This example illustrates the interpretation of an overall
result of 'no difference' from a meta-analysis. In such
situations, the onus lies on those championing the new
treatment to convince the community at large that there is
something special (producing both significant clinical and
statistical heterogeneity) about an individual trial or trials
Table I Relationship between a hazard ratio of 0.75 (reduction in
the relative risk of death of 25%) and absolute improvements over
different underlying survivalsa
Underlying Absolute improvements (0) in survival (%)
30 11
40 10
50 9
60 8
70 6
80 5
90 2
'All calculations assume proportional hazards.Meta-analysis of randomised trials
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with purports to show a benefit. In doing this we must be
aware of the possibility of extracting data-dependent results
and choosing the most extreme trials to make a point. By
contrast, substantial uncertainty may remain after a null
result because the confidence interval is wide and worthwhile
effects cannot be ruled out. In this case further large
prospective trials randomised may be required before the
issue is resolved.
Conclusion
Often a number ofrandomised clinical trials which address the
same or similar question are performed. There is a scientific
and ethical obligation to summarise and present this
information in an objective and quantitative manner. It will
usually be possible to summarise the overall results on a few
main end points in the form of a meta-analysis. Such a
summary provides the firmest basis on which to assess the
relative merits of competing therapies on end points such as
survival or disease-free survival. To ensure an unbiased and
complete summary it may be necessary to collect individual
patient data from every relevant trial. In some cases a meta-
analysis using data extracted from published reports may be
sufficient and it certainly is a useful first step given the length
of time it can take to collect individual patient data.
Whichever approach is adopted it should be noted that a
meta-analysis provides only a summary of the effect of
treatments on some main end points and that neither
individual trials nor meta-analysis provide prescriptions for
how individual patients should be treated. Nevertheless, the
clinical heterogeneity in a meta-analysis is likely to mean that
the results are of more practical value than those of any
individual trial. Issues such as the clinical relevance,
appropriate extrapolation to individual patients, toxicity and
implications on quality oflife and cost ofthe treatment cannot
easily be addressed within the meta-analysis. Currently, these
have to be assessed in detailed local, regional or perhaps
national studies. In this sense the meta-analysis acts only as
one, although essential, source of information.
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